Kochi-based pharma firm's new drug shows 'promising' results against COVID-19
The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore
PB Jayakumar | February 22, 2021 | Updated 15:08 IST
GPP-Baladol, a novel chemical entity (NCE) being developed by pharmaceutical research firm PNB Vesper Life Science for treating Covid-19 patients, claims to have shown promising results in the Phase 2b clinical trials. The pharma firm will soon seek Indian drug regulators' approval for emergency use in the country.
The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore. The clinical trial report will be submitted to the DCGI today seeking for an 'Emergency Use Authorisation' to treat hospitalised patients in the country in a clinical trial mode, said PNB Wesper, a Kochi-based pure NCE research firm with research operations in the UK, US and Germany.